Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: Diminishing treatment-related morbidity while maintaining efficacy

C. Kollmannsberger, C. Moore, K. N. Chi, N. Murray, S. Daneshmand, M. Gleave, B. Hayes-Lattin, C. R. Nichols

Research output: Contribution to journalArticlepeer-review

98 Scopus citations

Abstract

Background: With treatment leading to nearly uniform cure in clinical stage I nonseminomatous testicular cancer (CSI-NSGCT), diminishing treatment-related morbidity has become the primary concern. This study examined feasibility and outcome of active surveillance as treatment in an unselected CSI patient population. Materials and methods: All patients with CSI-NSGCT referred from 1998 to 2007 to the British Columbia Cancer Agency and the Oregon Testis Cancer Program were retrospectively reviewed. A total of 233 patients were identified, of which 223 chose active surveillance. Results: Vascular invasion (VI) was absent, present and unknown in 66%, 27% and 7% of cases, respectively. Overall, 49% of patients had embryonal predominant disease. Fifty-nine patients (26%) relapsed, all but one with good prognosis disease. VI was present in 30 relapsed patients. Most patients relapsed within 2 years (88%). Only 7 of 223 patients (3%) relapsed beyond 2 years. All relapses were in long-term remission following chemotherapy with or without retroperitoneal lymph node dissection (RPLND). Only 17 of 223 patients (8%) required postorchiectomy surgery. Disease-specific survival is 100% after a median follow-up of 52 months (3-136). No patient has required second-line chemotherapy. Conclusions: Active surveillance for all CSI-NSGCT patients is associated with excellent outcomes comparable with the best results reported with primary RPLND or adjuvant chemotherapy. Nearly 75% of patients are spared any therapy after orchiectomy.

Original languageEnglish (US)
Pages (from-to)1296-1301
Number of pages6
JournalAnnals of Oncology
Volume21
Issue number6
DOIs
StatePublished - Oct 29 2009

Keywords

  • Nonseminomatous testicular cancer
  • Stage I
  • Surveillance
  • Testis cancer

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: Diminishing treatment-related morbidity while maintaining efficacy'. Together they form a unique fingerprint.

Cite this